MedPath

Dalcetrapib

Generic Name
Dalcetrapib
Drug Type
Small Molecule
Chemical Formula
C23H35NO2S
CAS Number
211513-37-0
Unique Ingredient Identifier
3D050LIQ3H
Background

Dalcetrapib is under investigation for the treatment of Acute Coronary Syndrome.

Clinical Trials
Related News

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Phase 3
Recruiting
Conditions
Acute Coronary Syndrome
Interventions
Drug: Placebo
First Posted Date
2023-06-26
Last Posted Date
2025-04-24
Lead Sponsor
DalCor Pharmaceuticals
Target Recruit Count
2000
Registration Number
NCT05918861
Locations
🇵🇷

Research Site, Carolina, Puerto Rico

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Phase 2
Completed
Conditions
Covid19
Interventions
Other: Placebo
First Posted Date
2020-12-21
Last Posted Date
2022-12-07
Lead Sponsor
DalCor Pharmaceuticals
Target Recruit Count
227
Registration Number
NCT04676867
Locations
🇨🇦

Institut de Cardiologie de Montréal, Montréal, Quebec, Canada

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Phase 3
Completed
Conditions
Acute Coronary Syndrome
Interventions
Drug: Placebo
First Posted Date
2015-08-18
Last Posted Date
2022-10-12
Lead Sponsor
DalCor Pharmaceuticals
Target Recruit Count
6147
Registration Number
NCT02525939
Locations
🇬🇧

Research Site, Worthing, United Kingdom

🇨🇦

Institut de Cardiologie de Montreal, Montreal, Quebec, Canada

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Phase 3
Completed
Conditions
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions
Other: Background care
Drug: Placebo
First Posted Date
2012-01-25
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
2220
Registration Number
NCT01516541

A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2011-11-22
Last Posted Date
2019-12-17
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
6
Registration Number
NCT01476267

A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2011-06-02
Last Posted Date
2019-12-17
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
24
Registration Number
NCT01363999

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Phase 3
Completed
Conditions
Coronary Heart Disease
Interventions
Drug: placebo
First Posted Date
2011-03-25
Last Posted Date
2019-07-30
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
300
Registration Number
NCT01323153

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

Phase 3
Terminated
Conditions
Cardiovascular Disease
Interventions
Drug: Placebo
First Posted Date
2010-02-01
Last Posted Date
2020-03-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
936
Registration Number
NCT01059682

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

Phase 2
Completed
Conditions
Dyslipidemia
Interventions
Drug: Placebo
First Posted Date
2008-06-13
Last Posted Date
2020-01-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
292
Registration Number
NCT00697203

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Phase 3
Completed
Conditions
Coronary Heart Disease
Interventions
Drug: Evidence-based medical care for Acute Coronary Syndrome
Drug: Placebo
First Posted Date
2008-04-15
Last Posted Date
2020-01-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
15871
Registration Number
NCT00658515
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy